Those Who Got Shingles Vaccine Were 20% Less Likely to Get Dementia in Study of 280,000 Seniors 

​Recent research indicates that receiving the shingles vaccine may significantly reduce the risk of developing dementia. A study published in Nature analyzed health records of over 280,000 older adults in Wales and found that those vaccinated with Zostavax were 20% less likely to be diagnosed with dementia over the following seven years compared to their unvaccinated counterparts.

This finding adds to the growing body of evidence linking viral infections, particularly those caused by herpes viruses like the varicella-zoster virus responsible for shingles, to an increased risk of dementia. The virus can trigger inflammation and obstruct blood flow in the brain, potentially contributing to cognitive decline.

While the exact mechanisms remain under investigation, experts suggest that the vaccine may reduce neuroinflammation caused by virus reactivation or stimulate general immune responses protective against dementia. It’s important to note that the study focused on the live-attenuated shingles vaccine, Zostavax, which has been largely replaced by the more effective recombinant vaccine, Shingrix. Further research is needed to determine if Shingrix offers similar protective benefits against dementia. ​

These findings underscore the potential cognitive health benefits of shingles vaccination, offering a compelling reason for eligible individuals to consider immunization.​